AVANT Immunotherapeutics - 500 Beiträge pro Seite
eröffnet am 13.01.00 19:58:36 von
neuester Beitrag 19.03.00 17:08:51 von
neuester Beitrag 19.03.00 17:08:51 von
Beiträge: 41
ID: 50.633
ID: 50.633
Aufrufe heute: 0
Gesamt: 3.467
Gesamt: 3.467
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
heute 10:33 | 1857 | |
08.05.24, 11:56 | 1758 | |
vor 1 Stunde | 1282 | |
vor 23 Minuten | 1049 | |
vor 43 Minuten | 978 | |
vor 56 Minuten | 901 | |
gestern 17:20 | 824 | |
gestern 23:15 | 738 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.772,85 | +0,46 | 131 | |||
2. | 3. | 0,2170 | +3,33 | 125 | |||
3. | Neu! | 8,2570 | +96,67 | 108 | |||
4. | 4. | 156,46 | -2,31 | 103 | |||
5. | 14. | 5,7540 | -2,18 | 56 | |||
6. | 2. | 0,2980 | -3,87 | 50 | |||
7. | 5. | 2,3720 | -7,54 | 49 | |||
8. | 7. | 6,8000 | +2,38 | 38 |
Nasdaq = AVAN
Heute endlich der richtige Durchbruch.
Später mehr.
Heute endlich der richtige Durchbruch.
Später mehr.
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Hmmmm...
..bin heute auf Avant gestossen...
Ceti-1 in Phase 1/2 hat laut Website 8 MRD $ Marktpotential und TP-10
kommt dieses Jahr in Phase 3 ,ebenfalls Blockbusterpotential....
und ueberhaupt die Pipeline ist ja Rammelvoll...
NUR laut Yahoo hat AVAN Cashpositionen von nur 16 Mio$...
hmmmmm , reicht das wohl auf laengere Sicht ,das Teuerste steht ja erst noch an..
Warum gibt es keine Analystencoverages in U.S.zu einem derart vielversprechenden
Titel wie AVAN ? - Bitte nicht die "unentdeckte-Perle" Theorie ,ich moechte
wissen was da faul ist!
Regards
Rubininvest
..bin heute auf Avant gestossen...
Ceti-1 in Phase 1/2 hat laut Website 8 MRD $ Marktpotential und TP-10
kommt dieses Jahr in Phase 3 ,ebenfalls Blockbusterpotential....
und ueberhaupt die Pipeline ist ja Rammelvoll...
NUR laut Yahoo hat AVAN Cashpositionen von nur 16 Mio$...
hmmmmm , reicht das wohl auf laengere Sicht ,das Teuerste steht ja erst noch an..
Warum gibt es keine Analystencoverages in U.S.zu einem derart vielversprechenden
Titel wie AVAN ? - Bitte nicht die "unentdeckte-Perle" Theorie ,ich moechte
wissen was da faul ist!
Regards
Rubininvest
Was soll faul sein ?
Der Wert hat sich in kurzer Zeit fast vervierfacht.
Analysten befassen sich in den USA meistens erst mit Aktien, wenn sie dauerhaft über 5 $ notieren.
Nach dem strammen Anstieg ist eine Konsolidierung normal und wünschenswert.
Gruß biotech2001
Der Wert hat sich in kurzer Zeit fast vervierfacht.
Analysten befassen sich in den USA meistens erst mit Aktien, wenn sie dauerhaft über 5 $ notieren.
Nach dem strammen Anstieg ist eine Konsolidierung normal und wünschenswert.
Gruß biotech2001
Alles unter 5$ heißt eigentlich penny stock. Nur im Biobereich spricht man vornehm von small caps.
Ich denke der Weg für AVAN ist noch lang, aber er könnte sich lohnen (Bin bei 1,3 Euro rein)
Ich denke der Weg für AVAN ist noch lang, aber er könnte sich lohnen (Bin bei 1,3 Euro rein)
Heute wieder gut dabei.
Meine alte Liebe , noch unter T-Cell gekauft , gerade unter taxloss-Aspekten zur Hälfte verkauft, entwickelt sich zum Highflyer.
Alles ist möglich, selbst heute noch (7,9$) interessant. Sieht nach 5 - 10fachem aus. !
Alles ist möglich, selbst heute noch (7,9$) interessant. Sieht nach 5 - 10fachem aus. !
messages.yahoo.com/bbs?action=m&board=yahoo.a3.0c.7077312&to…
$10-Mrd-Dollar-pro-Jahr/Umsatz !!!
Die Ami´s sind verrückt nach Cholesterin-Tabletten, helfen zwar nix, aber wir wollen die (drugs) ja nicht selber essen...
10% von dem Kuchen für Avant Immunotherapeutics, das reicht mir, sieht besser aus als Celera Genomics, up,up and away...
$10-Mrd-Dollar-pro-Jahr/Umsatz !!!
Die Ami´s sind verrückt nach Cholesterin-Tabletten, helfen zwar nix, aber wir wollen die (drugs) ja nicht selber essen...
10% von dem Kuchen für Avant Immunotherapeutics, das reicht mir, sieht besser aus als Celera Genomics, up,up and away...
http://messages.yahoo.com/bbs?action=m&board=yahoo.a3.0c.707…
So geht´s !!
Wer Biotechs kauft, muss(!) Yahoo lesen !!!
So geht´s !!
Wer Biotechs kauft, muss(!) Yahoo lesen !!!
AVAN entwickelt sich in den USA zum Renner. Empfehlungen von Top-Biotech Managern häufen sich.
Gestern +20%
Gestern +20%
Hi Bio, Hi JSK,
im Moment scheint ihr beiden noch die einsamen Rufer in der
Wüste zu sein, was das Interesse für AVANT in der WO-Gemeinde
angeht. Unverständlich, so kontinuierlich wie sich der Wert
über die letzten Wochen nach oben gehangelt hat. Ich verstärke
euch jetzt mal, nachdem ich auch schon einige Wochen dabei bin,
bisher aber nur passiv mitgelesen hatte.
Mit dem deutlichen Plus von heute, wird sich die Lage was das
Interesse angeht, wohl ziemlich schnell ändern.
Verdient hätte die Aktie es allemal.
US-Postings sehen ebenfalls äußerst positiv aus, egal wohin man
sieht.
Auf daß es weiterhin schön gleichmäßig nach oben geht,
PI
im Moment scheint ihr beiden noch die einsamen Rufer in der
Wüste zu sein, was das Interesse für AVANT in der WO-Gemeinde
angeht. Unverständlich, so kontinuierlich wie sich der Wert
über die letzten Wochen nach oben gehangelt hat. Ich verstärke
euch jetzt mal, nachdem ich auch schon einige Wochen dabei bin,
bisher aber nur passiv mitgelesen hatte.
Mit dem deutlichen Plus von heute, wird sich die Lage was das
Interesse angeht, wohl ziemlich schnell ändern.
Verdient hätte die Aktie es allemal.
US-Postings sehen ebenfalls äußerst positiv aus, egal wohin man
sieht.
Auf daß es weiterhin schön gleichmäßig nach oben geht,
PI
Als ich mit Biotech anfing, wußte man in den Boards nicht einmal wie man das buchstabiert. Seit wenigen Wochen gibt es überall Experten und die threads sind kaum noch zu überblicken.
AVAN wird noch eine Weile brauchen, aber dann sind 80 $ drin.
AVAN wird noch eine Weile brauchen, aber dann sind 80 $ drin.
DR. WHEELER...
"The Study was not desigend to demonstrate efficacy" (CETI-1)
hmmmmm , ja o.k. ,kann man akzeptieren ,aber warum sagt er dann noch:
"We would not expect to see an antibody response"
Lässt er hier durchschimmern ,dass das Teil nicht funktionieren könnte
oder dass die Warscheinlichkeit nicht sehr gross ist? O.K. ,er hat es so
nicht gesagt aber ich meine zwischen den Zeilen gelesen jetzt...
Regards
Rubininvest
"The Study was not desigend to demonstrate efficacy" (CETI-1)
hmmmmm , ja o.k. ,kann man akzeptieren ,aber warum sagt er dann noch:
"We would not expect to see an antibody response"
Lässt er hier durchschimmern ,dass das Teil nicht funktionieren könnte
oder dass die Warscheinlichkeit nicht sehr gross ist? O.K. ,er hat es so
nicht gesagt aber ich meine zwischen den Zeilen gelesen jetzt...
Regards
Rubininvest
AVAN heute bei $ 9,25 bei fallendem NASDAQ-Gesamtmarkt...
Hallo,
besucht doch mal die Biotech Foren von Handelstag.de
http://www.handelstag.de/cgi-local/branchen?ind=bio
Gruss,
Andy
besucht doch mal die Biotech Foren von Handelstag.de
http://www.handelstag.de/cgi-local/branchen?ind=bio
Gruss,
Andy
Guten Abend Biofans!
Es ist mir ein Rätsel wieso der Kurs von Avant nach oben ging aber viele anderen kleinen Biowerte haben auch das Glück gehabt. Wenn man Avant anschaut merkt man, dass Avant kein einziges Produkt in der III Phase hat. Traurig! Diese Aktie reitet wie viele anderen Biowerte eine derzeitige Welle. Inzwischen glaube ich doch, dass die Welle schon längst vorbei ist und dass diese riesige Menge vom Investorens Geld kann man einfach nicht liegen lassen. Die richtigen Biowerte sind die die mit Genomen zu tun haben. Zum Bleistift: Curagen, Hyseq, Gen Therapeutics. Ich habe gesehen wie diese Werte einfach nach oben explodiert haben. Solange Inflations- und Zinsängste den Markt diktieren haben die kleinen Biowerte viel Luft nach oben. Viel Glück!
Yours truly,
GenMonster
Es ist mir ein Rätsel wieso der Kurs von Avant nach oben ging aber viele anderen kleinen Biowerte haben auch das Glück gehabt. Wenn man Avant anschaut merkt man, dass Avant kein einziges Produkt in der III Phase hat. Traurig! Diese Aktie reitet wie viele anderen Biowerte eine derzeitige Welle. Inzwischen glaube ich doch, dass die Welle schon längst vorbei ist und dass diese riesige Menge vom Investorens Geld kann man einfach nicht liegen lassen. Die richtigen Biowerte sind die die mit Genomen zu tun haben. Zum Bleistift: Curagen, Hyseq, Gen Therapeutics. Ich habe gesehen wie diese Werte einfach nach oben explodiert haben. Solange Inflations- und Zinsängste den Markt diktieren haben die kleinen Biowerte viel Luft nach oben. Viel Glück!
Yours truly,
GenMonster
Hi
bin heute zufällig auf Avant gestoßen. Was ich an Infos fand, gefällt mir gut - Immuntherapien sind weltweit ein Thema, das mehr und mehr Beachtung findet. Novartis setzt TP10 von Avant in der Transplantationschirurgie ein - das ist eine der besten Adressen überhaupt. Ich kann mir durchaus vorstellen, daß man hier mittelfristig einiges Geld verdienen kann. Guckt Euch mal die homepage an:
http://www.avantimmune.com
Grüße Dummi
bin heute zufällig auf Avant gestoßen. Was ich an Infos fand, gefällt mir gut - Immuntherapien sind weltweit ein Thema, das mehr und mehr Beachtung findet. Novartis setzt TP10 von Avant in der Transplantationschirurgie ein - das ist eine der besten Adressen überhaupt. Ich kann mir durchaus vorstellen, daß man hier mittelfristig einiges Geld verdienen kann. Guckt Euch mal die homepage an:
http://www.avantimmune.com
Grüße Dummi
http://www.insidertrader.com/freestuff/ticker_summary.asp?se…
Wie man hier sieht, steigen Institutionelle kontinuierlich ein ...
Wie man hier sieht, steigen Institutionelle kontinuierlich ein ...
http://www.sec.gov/Archives/edgar/data/744218/0000912057-00-…
Und wie man hier liest verkaufen Institutionelle eventuell auch.
Bei mir läuten die Alarmglocken.
Ich bin auf Avant vor ein paar Stunden durch stock-city aufmerksam geworden, habe mich schlau gemacht und fast nur positive Meinungen gefunden. Tja, bis auf obiges Statement. Das kann natürlich auch ganz harmlos sein. Aber mir gefällt es nicht.
Gruß aus Wien
Und wie man hier liest verkaufen Institutionelle eventuell auch.
Bei mir läuten die Alarmglocken.
Ich bin auf Avant vor ein paar Stunden durch stock-city aufmerksam geworden, habe mich schlau gemacht und fast nur positive Meinungen gefunden. Tja, bis auf obiges Statement. Das kann natürlich auch ganz harmlos sein. Aber mir gefällt es nicht.
Gruß aus Wien
Hy Biotech-Profis,
leider habe ich null Ahnung von dieser Branche. Gleichwohl ahne ich, dass da insgesamt was "abgeht".
Meine Fragen:
1. Kann ich in Avant noch einsteigen (ohne ein lemming zu werden)?
2. Welche sonstigen "bio-Aktien" sind kaufenswert bzw. haben power?
3. Wo gibt es solide und verständliche Infos zum Thema "bio-Aktien?
Danke vorab für eure Antworten. Eine Bitte noch: kein Gepushe!!!
haweha
leider habe ich null Ahnung von dieser Branche. Gleichwohl ahne ich, dass da insgesamt was "abgeht".
Meine Fragen:
1. Kann ich in Avant noch einsteigen (ohne ein lemming zu werden)?
2. Welche sonstigen "bio-Aktien" sind kaufenswert bzw. haben power?
3. Wo gibt es solide und verständliche Infos zum Thema "bio-Aktien?
Danke vorab für eure Antworten. Eine Bitte noch: kein Gepushe!!!
haweha
... warum antwortet mir keiner??????????
Zitat aus BÖRSE NOW, Februar 2000:
AVANT IMMUNOTHERAPHEUTICS: Option auf Blockbuster
Wenig spektakulär verlief im vergangenen Jahr die Kursentwicklung bei AI. Der Kurs pendelte um zwei US-Dollar. Diese Entwicklung ist vor dem Hintergrund der Nachrichten überraschend. Avant Immunotherapeutics verfügt über fünf Produkte in der klinischen Phase II, die vollständig von finanzstarken Partnern wie AstraZeneca, Novartis oder Yamanouchi finanziert worden sind. Das Risiko, ob eines der Präparate jemals von der US-Gesundheitsbehörde FDA zugelassen wird oder nicht, tragen also im vollem Umfang die Pharmapartner. Spätestens bis Ende 2000 sollen drei Präparate in die Phase III eintreten. Avant Immunotherapeutics ist daher vergleichbar mit einem Call auf Blockbuster-Medikamente. Mit der Cholesterinimpfung CETP, das jüngst die klinische Phase I erreicht hat, könnte Avant Immu. eines der bedeuterdsten Medikamente aller Zeiten entwickeln: ein bis zwei CETP-Impfungen pro Jahr sollen die krankhafte Ausweitung des Cholesterinspiegels verhindern. Spätestens wenn eines der Produkte in die klinische TestphaseIII eintritt, sollte der Aktienkurs durch die Decke gehen.
AVANT IMMUNOTHERAPHEUTICS: Option auf Blockbuster
Wenig spektakulär verlief im vergangenen Jahr die Kursentwicklung bei AI. Der Kurs pendelte um zwei US-Dollar. Diese Entwicklung ist vor dem Hintergrund der Nachrichten überraschend. Avant Immunotherapeutics verfügt über fünf Produkte in der klinischen Phase II, die vollständig von finanzstarken Partnern wie AstraZeneca, Novartis oder Yamanouchi finanziert worden sind. Das Risiko, ob eines der Präparate jemals von der US-Gesundheitsbehörde FDA zugelassen wird oder nicht, tragen also im vollem Umfang die Pharmapartner. Spätestens bis Ende 2000 sollen drei Präparate in die Phase III eintreten. Avant Immunotherapeutics ist daher vergleichbar mit einem Call auf Blockbuster-Medikamente. Mit der Cholesterinimpfung CETP, das jüngst die klinische Phase I erreicht hat, könnte Avant Immu. eines der bedeuterdsten Medikamente aller Zeiten entwickeln: ein bis zwei CETP-Impfungen pro Jahr sollen die krankhafte Ausweitung des Cholesterinspiegels verhindern. Spätestens wenn eines der Produkte in die klinische TestphaseIII eintritt, sollte der Aktienkurs durch die Decke gehen.
Hallo Leute,
Avan wird in der neusten Ausgabe von Taipan weiter empfohlen!
Zitat: "Wenn alles nach Plan läuft, hat Avan langfristig enormes Potenzial! Kann der CEPT-Impfstoff zur Marktreife entwickelt werden, würde er den Blockbuster Epogen vom Amgen weit in den Schatten stellen!!" Zitat ende.
Gruß Albatossa
Avan wird in der neusten Ausgabe von Taipan weiter empfohlen!
Zitat: "Wenn alles nach Plan läuft, hat Avan langfristig enormes Potenzial! Kann der CEPT-Impfstoff zur Marktreife entwickelt werden, würde er den Blockbuster Epogen vom Amgen weit in den Schatten stellen!!" Zitat ende.
Gruß Albatossa
AVAN ist ein Langfristinvestment mit erheblichen Potential bei dem man rechtzeitig einsteigen sollte.
Ich kann auch nur das eine sagen... jeder dachte der kurs würde mal nach unten gehen aber
dann lief er einfach ruhig nach oben weiter...
auch jetzt einzusteigen ist ratsam... meiner meinung nach...
schaut euch einfach nur den chart an... er sagt alles!
viele grusse an alle beteiligten...
stock-fan
dann lief er einfach ruhig nach oben weiter...
auch jetzt einzusteigen ist ratsam... meiner meinung nach...
schaut euch einfach nur den chart an... er sagt alles!
viele grusse an alle beteiligten...
stock-fan
Nach derzeitigem Kurs 1200 % seit knapp einem Jahr.
news von AVAN damit der wert nicht ganz verschwindet.!!!!
SmithKline Beecham Advances Clinical Development of the AVANT Rotavirus
Vaccine
NEEDHAM, Mass., March 8 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) announced today that SmithKline Beecham (NYSE:
SBH - news) has advanced clinical development of the human-derived, two-dose oral rotavirus vaccine licensed from AVANT. SmithKline presented its clinical
development program at a World Health Organization meeting on vaccine development in Geneva, Switzerland. AVANT developed the rotavirus vaccine and
licensed it to SmithKline Beecham Biologicals (SB Biologicals) of Rixensart, Belgium. In 1999, SB Biologicals assumed clinical and process development of the
vaccine after AVANT successfully completed a Phase II efficacy study in infants.
SB Biologicals has initiated Phase I/II bridging studies in Europe using its newly manufactured rotavirus vaccine, called Rotarix(TM). SB Biologicals is now planning
to start Phase III safety and efficacy studies in 2001 after review with health authorities.
``We are very pleased to be working with SB Biologicals in advancing worldwide development of this important pediatric vaccine candidate,`` said Una Ryan, Ph.D.,
President and Chief Executive Officer of AVANT Immunotherapeutics. ``We are confident that SmithKline`s expertise as a world- leading provider of vaccines
together with their established global distribution franchise will maximize the commercial potential of this product.``
``We are delighted to have achieved these important steps in our collaboration with AVANT, and we will continue to work to develop and commercialize this oral
rotavirus vaccine. Our ability to establish the commercial manufacturing process and the demonstrated efficacy of this vaccine candidate in the earlier Phase II trial
clearly suggests that we may have an excellent vaccine product for the world,`` said Dr. Jean Stephenne, President and General Manager, SmithKline Beecham
Biologicals.
The AVANT/SB Biologicals vaccine candidate is an attenuated vaccine derived from a naturally occurring isolate of rotavirus found in children. In the 215 infant
Phase II efficacy trial published in The Lancet in July 1999, approximately 90 percent of the vaccinated infants were protected from rotavirus disease with a
statistical significance of p < 0.001. Investigators from the Centers for Disease Control (CDC) have reported that natural rotavirus infection is not associated with
intussusception, a form of bowel obstruction.
In December 1997, AVANT licensed its rotavirus vaccine exclusively to SB Biologicals for further development and commercialization. Under the agreement, SB
Biologicals is responsible for all further development, and AVANT will receive milestone payments at various stages of development and regulatory approval. Also,
AVANT will be entitled to royalties upon commercialization of the vaccine.
Rotavirus is a major cause of acute diarrhea and dehydration in infants, which, in the absence of appropriate treatment, can rapidly lead to death. Approximately
500,000 infants in the United States require medical treatment annually, with 10-15% requiring hospitalization. Worldwide, rotavirus infection causes death in an
estimated 750,000 children annually, mostly in developing countries.
SmithKline Beecham Biologicals is located in Rixensart, Belgium, and is the center of all SmithKline`s activities in the field of vaccine research, development and
production. SB Biologicals employs over 600 research scientists who are devoted to discovering new vaccines and developing more cost-effective and convenient
combination products to prevent infections which cause serious medical problems worldwide. SB Biologicals produces 700 million doses of vaccines per year for
the developing and developed world. Every second, over 20 doses of SB Biologicals vaccines are distributed around the world. SmithKline Beecham -- one of the
world`s leading healthcare companies -- discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related
consumer products, and provides healthcare services including clinical laboratory testing and disease management.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune response to prevent
and treat disease. The company`s lead therapeutic program, now entering late stage clinical trials, focuses on compounds that inhibit inappropriate activation of the
complement cascade, a vital part of the body`s immune defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management
of atherosclerosis and Therapore(TM), a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The company and its
collaborators are developing vaccines using the proprietary adjuvants, Adjumer® and Micromer®, for the prevention of influenza, Lyme Disease and respiratory
syncytial virus (RSV). Through additional collaborations, AVANT is also developing an oral cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. and SB Biologicals can be obtained through the companies respective websites:
http://www.avantimmune.com and http://www.sb.com.
SmithKline Beecham Advances Clinical Development of the AVANT Rotavirus
Vaccine
NEEDHAM, Mass., March 8 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) announced today that SmithKline Beecham (NYSE:
SBH - news) has advanced clinical development of the human-derived, two-dose oral rotavirus vaccine licensed from AVANT. SmithKline presented its clinical
development program at a World Health Organization meeting on vaccine development in Geneva, Switzerland. AVANT developed the rotavirus vaccine and
licensed it to SmithKline Beecham Biologicals (SB Biologicals) of Rixensart, Belgium. In 1999, SB Biologicals assumed clinical and process development of the
vaccine after AVANT successfully completed a Phase II efficacy study in infants.
SB Biologicals has initiated Phase I/II bridging studies in Europe using its newly manufactured rotavirus vaccine, called Rotarix(TM). SB Biologicals is now planning
to start Phase III safety and efficacy studies in 2001 after review with health authorities.
``We are very pleased to be working with SB Biologicals in advancing worldwide development of this important pediatric vaccine candidate,`` said Una Ryan, Ph.D.,
President and Chief Executive Officer of AVANT Immunotherapeutics. ``We are confident that SmithKline`s expertise as a world- leading provider of vaccines
together with their established global distribution franchise will maximize the commercial potential of this product.``
``We are delighted to have achieved these important steps in our collaboration with AVANT, and we will continue to work to develop and commercialize this oral
rotavirus vaccine. Our ability to establish the commercial manufacturing process and the demonstrated efficacy of this vaccine candidate in the earlier Phase II trial
clearly suggests that we may have an excellent vaccine product for the world,`` said Dr. Jean Stephenne, President and General Manager, SmithKline Beecham
Biologicals.
The AVANT/SB Biologicals vaccine candidate is an attenuated vaccine derived from a naturally occurring isolate of rotavirus found in children. In the 215 infant
Phase II efficacy trial published in The Lancet in July 1999, approximately 90 percent of the vaccinated infants were protected from rotavirus disease with a
statistical significance of p < 0.001. Investigators from the Centers for Disease Control (CDC) have reported that natural rotavirus infection is not associated with
intussusception, a form of bowel obstruction.
In December 1997, AVANT licensed its rotavirus vaccine exclusively to SB Biologicals for further development and commercialization. Under the agreement, SB
Biologicals is responsible for all further development, and AVANT will receive milestone payments at various stages of development and regulatory approval. Also,
AVANT will be entitled to royalties upon commercialization of the vaccine.
Rotavirus is a major cause of acute diarrhea and dehydration in infants, which, in the absence of appropriate treatment, can rapidly lead to death. Approximately
500,000 infants in the United States require medical treatment annually, with 10-15% requiring hospitalization. Worldwide, rotavirus infection causes death in an
estimated 750,000 children annually, mostly in developing countries.
SmithKline Beecham Biologicals is located in Rixensart, Belgium, and is the center of all SmithKline`s activities in the field of vaccine research, development and
production. SB Biologicals employs over 600 research scientists who are devoted to discovering new vaccines and developing more cost-effective and convenient
combination products to prevent infections which cause serious medical problems worldwide. SB Biologicals produces 700 million doses of vaccines per year for
the developing and developed world. Every second, over 20 doses of SB Biologicals vaccines are distributed around the world. SmithKline Beecham -- one of the
world`s leading healthcare companies -- discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related
consumer products, and provides healthcare services including clinical laboratory testing and disease management.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune response to prevent
and treat disease. The company`s lead therapeutic program, now entering late stage clinical trials, focuses on compounds that inhibit inappropriate activation of the
complement cascade, a vital part of the body`s immune defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management
of atherosclerosis and Therapore(TM), a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The company and its
collaborators are developing vaccines using the proprietary adjuvants, Adjumer® and Micromer®, for the prevention of influenza, Lyme Disease and respiratory
syncytial virus (RSV). Through additional collaborations, AVANT is also developing an oral cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. and SB Biologicals can be obtained through the companies respective websites:
http://www.avantimmune.com and http://www.sb.com.
und hier sind noch die zahlen für 1999
AVANT Reports Fourth Quarter And Fiscal Year 1999 Financial Results
NEEDHAM, Mass., March 7 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today reported financial results for the fourth quarter
and year ended December 31, 1999. The Company reported a net loss of $3.7 million, or $0.08 per share, for the fourth quarter of 1999 compared to a net loss of
$2.3 million, or $0.05 per share, for the fourth quarter of 1998. Net loss for the fourth quarter of 1999 increased $1.3 million, or 58.0%, over the net loss for the
fourth quarter of 1998. The increase in net loss is primarily due to the lack of revenues in the 1999 period combined with the significant increase in clinical trials cost
and expense associated with the manufacture of clinical materials for Company-funded clinical studies.
For the twelve months ended December 31, 1999, the Company reported a net loss of $11.3 million, or $0.26 per share, compared to a net loss of $51.8 million,
or $1.56 per share, for the same period in 1998. The net loss for the year ended December 31, 1998 includes a charge of $44,630,000 for purchased in-process
research and development related to the acquisition of Virus Research Institute, Inc. (VRI) in August 1998. Excluding the charge for purchased in-process research
and development in 1998, the net loss for 1999 increased 57.7% to $11.3 million, or $0.26 per share, compared to $7.2 million, or $0.22 per share, for 1998. The
increase in operating expense for 1999 compared to 1998 is primarily due to: (i) a full year of operations of VRI in 1999 versus four months in 1998, combined with
an increase of goodwill amortization expense of $0.7 million; (ii) increased costs associated with conducting the Phase I clinical trial of CETi-1 and the Phase I/II
clinical trial of TP10, both of which commenced in 1999; and (iii) an increase in expense associated with the manufacture of clinical materials. At December 31,
1999, the Company reported cash and cash equivalents, including restricted cash, of $13.8 million.
``Over the past year, we achieved several notable clinical and scientific milestones,`` said Una S. Ryan, president and chief executive officer of AVANT
Immunotherapeutics, Inc. ``In particular, we are extremely pleased to be advancing both TP10, our lead complement inhibitor, and CETi-1, our novel investigational
vaccine to prevent or treat atherosclerosis, through clinical development. By demonstrating the clinical potential of our products, developing some of our most
promising products on our own and creating partnerships for the continued development and commercialization of other products, we believe we can both minimize
risk and maximize the potential value of AVANT to our investors. Also, we have substantially improved our cash position with the receipt of $6 million from
Novartis in January.``
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune response to prevent
and treat disease. The company`s lead therapeutic program, now entering late stage clinical trials, focuses on compounds that inhibit inappropriate activation of the
complement cascade, a vital part of the body`s immune defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management
of atherosclerosis and Therapore(TM), a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The company and its
collaborators are developing vaccines using the proprietary adjuvants, Adjumer® and Micromer®, for the prevention of influenza, Lyme Disease and respiratory
syncytial virus (RSV). Through additional collaborations, AVANT is also developing an oral human rotavirus vaccine and a cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through the Company`s site on the World Wide Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect AVANT`s
current views with respect to future events and financial performance. The words ``believe,`` ``expect,`` ``anticipate,`` and similar expressions identify forward-looking
statements. Investors should not rely on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: (1) the ability to
successfully complete development and commercialization of TP10, CETi-1 and other products: (2) the cost, scope and results of preclinical and clinical testing; (3)
the ability to successfully complete product research and further development, including clinical studies of TP10, CETi-1 and other products; (4) changes in existing
and potential relationships with corporate collaborators; (5) the time, cost and uncertainty of obtaining regulatory approvals; (6) the ability to obtain substantial
additional funding; (7) the ability to develop and commercialize products before competitors; and (8) other factors detailed from time to time in filings with the
Securities and Exchange Commission.
AVANT IMMUNOTHERAPEUTICS, INC.
CONSOLIDATED STATEMENTS
OF OPERATIONS
DATA Quarter Ended December 31, Year Ended December 31,
1999 1998 1999 1998
OPERATING REVENUE
Product Sales, Product
Development and
Licensing
Agreements $-- $1,068,200 $1,483,500 $2,150,400
OPERATING EXPENSE
Research and
Development 2,177,900 1,765,900 7,871,800 5,725,400
Charge for Purchased
In-Process Research
and Development -- -- -- 44,630,000
Amortization of
Goodwill 137,300 413,400 1,275,800 546,400
Other Operating
Expense 1,544,200 1,424,700 4,280,200 3,642,500
Total Operating
Expense 3,859,400 3,604,000 13,427,800 54,544,300
Operating Loss (3,859,400) (2,535,800) (11,944,300) (52,393,900)
Non Operating
Income, Net 200,300 220,200 635,200 594,200
Net Loss $(3,659,100) $(2,315,600) $(11,309,100) $(51,799,700)
Basic and Diluted
Net Loss per
Common Share $(0.08) $(0.05) $(0.26) $(1.56)
Weighted Average
Common Shares
Outstanding 48,064,700 42,506,400 44,076,400 33,177,200
CONSOLIDATED BALANCE
SHEET DATA December 31, December 31,
1999 1998
Cash, Cash Equivalents
and Marketable Securities
Including Restricted Cash $13,836,000 $14,955,300
Working Capital 12,289,200 12,298,100
Accumulated Deficit 133,345,400 122,036,300
Total Stockholders` Equity 17,413,000 18,769,600
AVANT Reports Fourth Quarter And Fiscal Year 1999 Financial Results
NEEDHAM, Mass., March 7 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today reported financial results for the fourth quarter
and year ended December 31, 1999. The Company reported a net loss of $3.7 million, or $0.08 per share, for the fourth quarter of 1999 compared to a net loss of
$2.3 million, or $0.05 per share, for the fourth quarter of 1998. Net loss for the fourth quarter of 1999 increased $1.3 million, or 58.0%, over the net loss for the
fourth quarter of 1998. The increase in net loss is primarily due to the lack of revenues in the 1999 period combined with the significant increase in clinical trials cost
and expense associated with the manufacture of clinical materials for Company-funded clinical studies.
For the twelve months ended December 31, 1999, the Company reported a net loss of $11.3 million, or $0.26 per share, compared to a net loss of $51.8 million,
or $1.56 per share, for the same period in 1998. The net loss for the year ended December 31, 1998 includes a charge of $44,630,000 for purchased in-process
research and development related to the acquisition of Virus Research Institute, Inc. (VRI) in August 1998. Excluding the charge for purchased in-process research
and development in 1998, the net loss for 1999 increased 57.7% to $11.3 million, or $0.26 per share, compared to $7.2 million, or $0.22 per share, for 1998. The
increase in operating expense for 1999 compared to 1998 is primarily due to: (i) a full year of operations of VRI in 1999 versus four months in 1998, combined with
an increase of goodwill amortization expense of $0.7 million; (ii) increased costs associated with conducting the Phase I clinical trial of CETi-1 and the Phase I/II
clinical trial of TP10, both of which commenced in 1999; and (iii) an increase in expense associated with the manufacture of clinical materials. At December 31,
1999, the Company reported cash and cash equivalents, including restricted cash, of $13.8 million.
``Over the past year, we achieved several notable clinical and scientific milestones,`` said Una S. Ryan, president and chief executive officer of AVANT
Immunotherapeutics, Inc. ``In particular, we are extremely pleased to be advancing both TP10, our lead complement inhibitor, and CETi-1, our novel investigational
vaccine to prevent or treat atherosclerosis, through clinical development. By demonstrating the clinical potential of our products, developing some of our most
promising products on our own and creating partnerships for the continued development and commercialization of other products, we believe we can both minimize
risk and maximize the potential value of AVANT to our investors. Also, we have substantially improved our cash position with the receipt of $6 million from
Novartis in January.``
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune response to prevent
and treat disease. The company`s lead therapeutic program, now entering late stage clinical trials, focuses on compounds that inhibit inappropriate activation of the
complement cascade, a vital part of the body`s immune defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management
of atherosclerosis and Therapore(TM), a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The company and its
collaborators are developing vaccines using the proprietary adjuvants, Adjumer® and Micromer®, for the prevention of influenza, Lyme Disease and respiratory
syncytial virus (RSV). Through additional collaborations, AVANT is also developing an oral human rotavirus vaccine and a cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through the Company`s site on the World Wide Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements which reflect AVANT`s
current views with respect to future events and financial performance. The words ``believe,`` ``expect,`` ``anticipate,`` and similar expressions identify forward-looking
statements. Investors should not rely on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: (1) the ability to
successfully complete development and commercialization of TP10, CETi-1 and other products: (2) the cost, scope and results of preclinical and clinical testing; (3)
the ability to successfully complete product research and further development, including clinical studies of TP10, CETi-1 and other products; (4) changes in existing
and potential relationships with corporate collaborators; (5) the time, cost and uncertainty of obtaining regulatory approvals; (6) the ability to obtain substantial
additional funding; (7) the ability to develop and commercialize products before competitors; and (8) other factors detailed from time to time in filings with the
Securities and Exchange Commission.
AVANT IMMUNOTHERAPEUTICS, INC.
CONSOLIDATED STATEMENTS
OF OPERATIONS
DATA Quarter Ended December 31, Year Ended December 31,
1999 1998 1999 1998
OPERATING REVENUE
Product Sales, Product
Development and
Licensing
Agreements $-- $1,068,200 $1,483,500 $2,150,400
OPERATING EXPENSE
Research and
Development 2,177,900 1,765,900 7,871,800 5,725,400
Charge for Purchased
In-Process Research
and Development -- -- -- 44,630,000
Amortization of
Goodwill 137,300 413,400 1,275,800 546,400
Other Operating
Expense 1,544,200 1,424,700 4,280,200 3,642,500
Total Operating
Expense 3,859,400 3,604,000 13,427,800 54,544,300
Operating Loss (3,859,400) (2,535,800) (11,944,300) (52,393,900)
Non Operating
Income, Net 200,300 220,200 635,200 594,200
Net Loss $(3,659,100) $(2,315,600) $(11,309,100) $(51,799,700)
Basic and Diluted
Net Loss per
Common Share $(0.08) $(0.05) $(0.26) $(1.56)
Weighted Average
Common Shares
Outstanding 48,064,700 42,506,400 44,076,400 33,177,200
CONSOLIDATED BALANCE
SHEET DATA December 31, December 31,
1999 1998
Cash, Cash Equivalents
and Marketable Securities
Including Restricted Cash $13,836,000 $14,955,300
Working Capital 12,289,200 12,298,100
Accumulated Deficit 133,345,400 122,036,300
Total Stockholders` Equity 17,413,000 18,769,600
Als einer der wenigen Werte konnte sich AVAN gestern abend in New York bei hohem Umsatz mit einem Plus von 3,4% behaupten.
Hallo zusammen... Wollte...bei 1.5 Euro einsteigen ...Ich Idiot habs leider erst bei über 10 Euro geschaft Tja verzehnfachung verschenkt . Bei Softbank deselbe wollte schon bei 70 Euro einsteigen . Bin leider erst bei 700 eingestiegen.... Tja hätte mich um Haaresbreite pensionieren lassen können. schei....e , schei....e !!!! Bei avant sage ich nur eins...!!!!!! DER CHART SAGT ALLES !!!!!!! Besser jetzt alls nie !!! kaufen !!! Der Kurs ist erst seit 2 Monaten in Fahrt und noch nicht zu bekannt eher eine unentdekte Perle . Ich ärgere mich whol noch lang nicht früher kekauft zu haben . Da ich immer mit hohen Einsätzen spiele ärgert mich die verpasste Pension !!!! Tja , Tja , Tja ... gebe nicht auf,nein ich gebe nicht auf , nein ich fass es nicht trotz meiner Gewinne.... Ich denke einigen von euch spreche ich aus der Sele!!!!!!!?????
Jeder kennt verpasste Gelegenheiten, meine war Medarex zu 4$...
Ob Avant noch weiter so steigt ? Noch ist alles reine Spekulation auf kommende Zeiten...
Ob Avant noch weiter so steigt ? Noch ist alles reine Spekulation auf kommende Zeiten...
Ich bin schon seit einiger Zeit auf der Suche nach aussichtsreichen Biotech-Werten.
Da ich selbst Mediziner bin, liegt mein Hauptaugenmerk beim research auf der jeweiligen Produktpalette. Nach dem Studium von ca. 30 Werten, hab` ich nun Avant mit in die "Endausscheidung" genommen. Könnte mir jemand von Euch was zur Marktkapitalisierung sagen, am besten mit Quellenangabe.
Vielen Dank und schönes Wochenende noch,
Gruß, Fussl
Da ich selbst Mediziner bin, liegt mein Hauptaugenmerk beim research auf der jeweiligen Produktpalette. Nach dem Studium von ca. 30 Werten, hab` ich nun Avant mit in die "Endausscheidung" genommen. Könnte mir jemand von Euch was zur Marktkapitalisierung sagen, am besten mit Quellenangabe.
Vielen Dank und schönes Wochenende noch,
Gruß, Fussl
Derzeit ist AVAN Spielball der Biotech-Hype, bis dort cash zu sehen ist, das dauert noch 2-5 Jahre.
Und ne neue AdHoc! Vorbörse sieht gut aus! zur Zeit bei 16 $!
Tuesday March 14, 8:31 am Eastern Time
Company Press Release
SOURCE: AVANT Immunotherapeutics, Inc.
AVANT`s Complement Inhibitor, TP10, Granted
Orphan Drug Status as Treatment for Infants
Undergoing Cardiac Surgery
NEEDHAM, Mass., March 14 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today
announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to AVANT`s lead complement
inhibitor, TP10, as a potential treatment to reduce the consequences of reperfusion injury and to improve post-operative
outcomes in infants undergoing cardiac surgery. Products designated as Orphan Drugs gain seven years of marketing exclusivity
for the designated indications once they receive FDA approval, according to the Orphan Drug Act of 1983. AVANT recently
completed enrollment in an open-label, Phase I/II safety and efficacy trial of TP10 in infants undergoing cardiac surgery
requiring cardiopulmonary bypass (CPB).
``Receiving orphan drug designation for TP10 further strengthens the competitive position of this product,`` said Una S. Ryan,
Ph.D., President and Chief Executive Officer of AVANT. ``We plan to report results from our Phase I/II trial during the
second quarter and expect to initiate a pivotal Phase III trial in infants undergoing cardiac surgery by the end of the year.``
During cardiac surgery on CPB, complement becomes activated when the heart is stopped and circulation is subsequently
restored, causing reperfusion injury, and by the exposure of blood to the heart-lung machine. Complement activation can impair
the functions of the heart, lungs and other organs and can contribute significantly to postoperative complications that prolong
hospital stays, increase medical expenses and impair patient recovery. Approximately 15,000 infants in the United States
undergo cardiac surgery to correct congenital heart defects each year.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness
the human immune response to prevent and treat disease. The Company`s lead therapeutic program, now in late stage clinical
trials, focuses on compounds that inhibit the inappropriate activity of the complement cascade, a vital part of the body`s immune
defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management of atherosclerosis
and Therapore?, a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The
Company and its collaborators are developing vaccines using its proprietary adjuvants, Adjumer® and Micromer®, for the
prevention of influenza, respiratory syncytial virus (RSV), Lyme disease, and several other vaccine targets. Through additional
collaborations, AVANT is also developing an oral human rotavirus vaccine and a cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through the Company`s site on the World Wide
Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking
statements which reflect AVANT`s current views with respect to future events and financial performance. The words ``believe,``
``expect,`` ``anticipate,`` and similar expressions identify forward-looking statements. Investors should not rely on
forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are
not limited to: (1) the ability to successfully complete development and commercialization of TP10 for use in infants undergoing
cardiac surgery and other purposes and of other products; (2) the cost, scope and results of ongoing safety and efficacy trials
of TP10 and other preclinical and clinical testing; (3) the ability to successfully complete product research and further
development, including animal, pre-clinical and clinical studies of TP10 and other products; (4) changes in existing and potential
relationships with corporate collaborators; (5) the time, cost and uncertainty of obtaining regulatory approvals to use TP10,
among other purposes, for infants undergoing cardiac surgery and for other products; (6) the ability to obtain substantial
additional funding; (7) the ability to develop and commercialize products before competitors; and (8) other factors detailed
from time to time in filings with the Securities and Exchange Commission.
SOURCE: AVANT Immunotherapeutics, Inc.
Tuesday March 14, 8:31 am Eastern Time
Company Press Release
SOURCE: AVANT Immunotherapeutics, Inc.
AVANT`s Complement Inhibitor, TP10, Granted
Orphan Drug Status as Treatment for Infants
Undergoing Cardiac Surgery
NEEDHAM, Mass., March 14 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) today
announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to AVANT`s lead complement
inhibitor, TP10, as a potential treatment to reduce the consequences of reperfusion injury and to improve post-operative
outcomes in infants undergoing cardiac surgery. Products designated as Orphan Drugs gain seven years of marketing exclusivity
for the designated indications once they receive FDA approval, according to the Orphan Drug Act of 1983. AVANT recently
completed enrollment in an open-label, Phase I/II safety and efficacy trial of TP10 in infants undergoing cardiac surgery
requiring cardiopulmonary bypass (CPB).
``Receiving orphan drug designation for TP10 further strengthens the competitive position of this product,`` said Una S. Ryan,
Ph.D., President and Chief Executive Officer of AVANT. ``We plan to report results from our Phase I/II trial during the
second quarter and expect to initiate a pivotal Phase III trial in infants undergoing cardiac surgery by the end of the year.``
During cardiac surgery on CPB, complement becomes activated when the heart is stopped and circulation is subsequently
restored, causing reperfusion injury, and by the exposure of blood to the heart-lung machine. Complement activation can impair
the functions of the heart, lungs and other organs and can contribute significantly to postoperative complications that prolong
hospital stays, increase medical expenses and impair patient recovery. Approximately 15,000 infants in the United States
undergo cardiac surgery to correct congenital heart defects each year.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness
the human immune response to prevent and treat disease. The Company`s lead therapeutic program, now in late stage clinical
trials, focuses on compounds that inhibit the inappropriate activity of the complement cascade, a vital part of the body`s immune
defense system. AVANT is also developing on its own a proprietary therapeutic vaccine for the management of atherosclerosis
and Therapore?, a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers. The
Company and its collaborators are developing vaccines using its proprietary adjuvants, Adjumer® and Micromer®, for the
prevention of influenza, respiratory syncytial virus (RSV), Lyme disease, and several other vaccine targets. Through additional
collaborations, AVANT is also developing an oral human rotavirus vaccine and a cholera vaccine.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through the Company`s site on the World Wide
Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking
statements which reflect AVANT`s current views with respect to future events and financial performance. The words ``believe,``
``expect,`` ``anticipate,`` and similar expressions identify forward-looking statements. Investors should not rely on
forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause
actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are
not limited to: (1) the ability to successfully complete development and commercialization of TP10 for use in infants undergoing
cardiac surgery and other purposes and of other products; (2) the cost, scope and results of ongoing safety and efficacy trials
of TP10 and other preclinical and clinical testing; (3) the ability to successfully complete product research and further
development, including animal, pre-clinical and clinical studies of TP10 and other products; (4) changes in existing and potential
relationships with corporate collaborators; (5) the time, cost and uncertainty of obtaining regulatory approvals to use TP10,
among other purposes, for infants undergoing cardiac surgery and for other products; (6) the ability to obtain substantial
additional funding; (7) the ability to develop and commercialize products before competitors; and (8) other factors detailed
from time to time in filings with the Securities and Exchange Commission.
SOURCE: AVANT Immunotherapeutics, Inc.
Habe über Umwegen von Goodnews Ende März gehört.
Ist einem von Euch irgendwas bekannt ?
Ist einem von Euch irgendwas bekannt ?
AVANT hat klassisch konsolidiert und wird in den kommenden Wochen mit Sicherheit die Marke von 20 Euro überschreiten. Wer bei Kursen von 12 -13 Euro jetzt nicht einsteigt ist selber schuld.
Dein Wort in Gottes Ohr.
Bei den vielen Produkten die Avant noch hat wird der Kurs auf jeden Fall nochmal losgehen.
Bei den vielen Produkten die Avant noch hat wird der Kurs auf jeden Fall nochmal losgehen.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
118 | ||
83 | ||
80 | ||
72 | ||
69 | ||
38 | ||
30 | ||
29 | ||
28 | ||
24 |
Wertpapier | Beiträge | |
---|---|---|
21 | ||
20 | ||
16 | ||
14 | ||
14 | ||
13 | ||
13 | ||
13 | ||
12 | ||
11 |